Risum Malene, Dufva Inge Høgh
Haematologisk Afdeling L, Herlev Hospital, DK-2730 Herlev, Denmark.
Ugeskr Laeger. 2010 Feb 8;172(6):452-5.
Lenalidomide is the first drug to induce transfusion independence and cytogenetic remission in patients with myelodysplastic syndrome (MDS) with deletion 5q and low or intermediate risk score. Transfusion independence can be obtained within five weeks. Three out of four patients also obtain a cytogenetic response to treatment. However, concern has arisen about the possibility of an increased risk of transformation to acute myeloid leukaemia. A multicenter, randomised, placebo-controlled study with long-term follow-up is needed.
来那度胺是首个能使5q缺失且低或中危评分的骨髓增生异常综合征（MDS）患者实现输血独立和细胞遗传学缓解的药物。输血独立可在五周内实现。四分之三的患者在治疗后还能获得细胞遗传学缓解。然而，对于转化为急性髓系白血病风险增加的可能性已引发关注。因此需要开展一项长期随访的多中心、随机、安慰剂对照研究。
